Tinnitus Treatment: Neurodegenerative Strategy Insights

Tinnitus, the perception of sound without an external source, affects millions. Its persistence is now understood as a problem of faulty brain rewiring, or maladaptive neuroplasticity. Researchers J L Liu and Peng Liu propose a direct link between this process and the mechanisms that drive neurodegenerative diseases. Their analysis suggests that drugs developed for conditions like Alzheimer’s could be repurposed to treat tinnitus by targeting its root causes in the brain.

## Shared Pathology: When the Auditory Brain Misfires

The central argument is that chronic tinnitus and neurodegeneration are not the same condition, but they operate on similar biological pathways. When sensory input from the ears is reduced—due to hearing loss, for example—the brain’s auditory system can become hyperactive and reorganize in unhelpful ways. This involves specific, harmful processes: chronic, low-grade **neuroinflammation** that damages neurons; **synaptic dysfunction** that impairs communication between brain cells; and **excitotoxicity**, where excessive glutamate, a key neurotransmitter, overstimulates and kills neurons.

These are the same hallmarks found in the brains of patients with major neurodegenerative disorders. “The complex pathophysiology of tinnitus shares significant mechanistic parallels with neurodegenerative processes,” Liu and Liu write. This overlap isn’t just theoretical; it provides a list of proven biological targets that existing neuroprotective drugs are designed to hit.

## Repurposing Neuroprotective Drugs for Tinnitus

The review systematically examines three main therapeutic strategies borrowed from neurodegeneration research. First, **targeting neuroinflammation**. Drugs that inhibit specific inflammatory signaling molecules (like TNF-α or IL-1β) have reduced tinnitus-like behavior in animal models. These agents aim to quiet the inflammatory “background noise” in the brain that sustains tinnitus.

Second, **modulating neurotrophic factors**. These are proteins that support neuron survival and health. Brain-derived neurotrophic factor (BDNF) and its receptor, TrkB, are often dysregulated in both tinnitus and neurodegeneration. Approaches to boost BDNF signaling, including certain drugs and possibly even blast trauma recovery via TrkB pathways, could help stabilize malfunctioning auditory circuits.

Third, **mitigating glutamate excitotoxicity**. This is a prime candidate for intervention. Memantine, a drug used in Alzheimer’s disease that blocks overactive glutamate receptors (NMDA receptors), has shown mixed but promising results in tinnitus clinical trials. Other anti-glutamate compounds are under investigation to prevent the neuronal damage caused by this excitatory overload.

## From Animal Models to Human Trials: The Translational Gap

Preclinical evidence from animal studies forms the backbone of this proposal. In rodent models of tinnitus, drugs from all three categories have demonstrated an ability to reduce behavioral signs of tinnitus and normalize aberrant brain activity. The methodology here is clear: induce hearing loss or noise trauma, confirm the development of tinnitus-like behavior, administer the neuroprotective drug, and measure improvements.

The translational landscape for humans, however, is less defined. While some drugs like memantine have entered clinical trials, results have been inconsistent. The authors note that successful repurposing may require refining drug delivery, identifying which tinnitus patients have the specific “neurodegenerative-like” subtype, and optimizing treatment timing. The approach is logical, but large-scale, targeted clinical studies are needed. This precision-medicine angle aligns with broader trends in AI’s judo strategy in hearing health, which focuses on using data to match the right intervention to the individual.

## Practical Implications for Future Treatment

For patients and clinicians, this research framework shifts the perspective on tinnitus from a mysterious ear noise to a potentially modifiable brain condition with a known pharmacology. The immediate implication is that the pipeline for new tinnitus drugs could be accelerated by testing already-developed neuroprotective agents.

It also reinforces the importance of a whole-brain approach to treatment. The non-auditory brain networks involved in tinnitus—those governing attention, emotion, and memory—are also heavily affected in neurodegeneration. This explains the high comorbidity of tinnitus and anxiety and suggests that effective treatment may need to address these broader networks. Techniques like noninvasive brain stimulation, which can modulate plasticity, may work well alongside these pharmacological strategies.

Furthermore, managing co-factors that exacerbate both neurodegeneration and tinnitus, such as poor sleep and stress, becomes even more critical. The chronic stress of tinnitus can worsen neuroinflammation, creating a vicious cycle. Interventions like evidence-based sleep hygiene could therefore play a supportive role in a comprehensive treatment plan.

**Source:** This article is based on the review “Repurposing Neurodegenerative Disease Therapeutics for Tinnitus Intervention: A New Strategic Approach” by J L Liu and Peng Liu (DOI: 10.3389/fnagi.2026.1835649).